Abstract
AimsMedications and costs of drug for diabetic retinopathy in outpatient in China have not been evaluated. The purpose of this study was to evaluate the hypoglycemic drugs and medical costs of diabetic retinopathy patients in the Beijing medical insurance system, analyze the characteristics of outpatient treatment, and investigate the changes in the quantity and cost of hypoglycemic drugs from 2016 to 2018. MethodsThis is a retrospective observational study, including diabetic patients with outpatient records in Beijing medical insurance from 2016 to 2018. Data on oral hypoglycemic drugs, insulin and non-hypoglycemic drugs, complications, treatment strategies, and annual medical costs were recorded. ResultsA total of 2,853,036 diabetic patients in Beijing medical insurance were enrolled in this study. 4.19 %–4.67 % of patients were diagnosed with retinopathy. Patients with retinopathy have more diabetic complications (1.65 ± 0.71 vs 0.18 ± 0.44. p < .0001), and use more drugs (5.11 ± 2.60 vs 3.85 ± 2.34, p < .0001), the annual total drug cost is also higher (¥ 13,836 ± 11,244 vs ¥ 10,030 ± 9375, p < .0001). The numbers of medication in retinopathy patients increased (5.11 ± 2.60 vs 4.95 ± 2.57, p < .0001), and the annual total drug cost (¥13,836 ± 11,244 vs ¥15,642 ± 13,344, p < .0001) decreased in 2018 compared with 2016. ConclusionsPatients with retinopathy were associated with more complications. Compared with patients without retinopathy, the number of medications and total medical costs were significantly increased. From 2016 to 2018, there was an increase in the number of medication treatments for patients with retinopathy, but a decrease in cost.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.